Your search for dabigatran returned 42 results

Despite trend toward lower stroke risk with high dose

A subgroup analysis from the RE-LY trial has demonstrated that in patients with atrial fibrillation (AF), twice-daily dabigatran etexilate has better efficacy and lower rates of major bleeding when compared with warfarin, as reported at ACC.11, the American College of Cardiology’s 60th Annual Scientific Session.

Combining dabigatran with certain statin medications could raise the odds for major hemorrhage in patients with atrial fibrillation, according to a study published online in CMAJ, the journal of the Canadian Medical Association.

The researchers found the risk of GI bleeding was lower for apixaban versus dabigatran or rivaroxaban.

The increased number of post-marketing reports of bleeding associated with use of dabigatran seems to be an example of stimulated reporting and may not represent an increased bleeding risk.

Dabigatran is associated with higher risks of major bleeding and gastrointestinal bleeding compared with warfarin, but patients taking dabigatran also have a reduced risk of intracranial bleeding compared with those taking warfarin, according to new research.

Efficacy similar to aspirin for preventing recurrent stroke after embolic stroke of undetermined source

For patients with venous thromboembolism, extended treatment with dabigatran is noninferior to warfarin.

Researchers performed a retrospective cohort study to compare incidence of stroke, bleeding, and myocardial infarction in patients with atrial fibrillation initiating dabigatran or warfarin (n=25,289 for each) from November 2010 to May 2014.

Increase in risk of intracranial hemorrhage, major GI bleeding in a-fib patients taking rivaroxaban